^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CD19.t-haNK

i
Other names: CD19.t-haNK
Associations
Company:
ImmunityBio
Drug class:
CD19 inhibitor
Associations
6ms
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=20, Recruiting, ImmunityBio, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
8ms
New P1 trial • Combination therapy
|
Rituxan (rituximab) • CD19.t-haNK
10ms
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=20, Not yet recruiting, ImmunityBio, Inc. | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Sep 2024 --> Mar 2026
Trial completion date • Trial primary completion date • Combination therapy
|
CD20 positive
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
over1year
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=20, Not yet recruiting, ImmunityBio, Inc. | Initiation date: Apr 2023 --> Sep 2023
Trial initiation date • Combination therapy
|
CD20 positive
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
over1year
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=20, Not yet recruiting, ImmunityBio, Inc. | Initiation date: Nov 2022 --> Mar 2023
Trial initiation date • Combination therapy
|
CD19 (CD19 Molecule)
|
CD20 positive
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
almost2years
New P1 trial • Combination therapy
|
CD19 (CD19 Molecule)
|
CD20 positive
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
over2years
CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma. (PubMed, Cytotherapy)
Expression of CCR7 receptor by off-the-shelf t-haNK cells improves their homing toward lymph node chemokines both in vitro and in vivo, resulting in superior tumor control.
Preclinical • Journal • IO biomarker
|
CD19 (CD19 Molecule) • CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
|
CD19 expression • CCR7 expresion
|
CD19.t-haNK
over3years
QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
P1, N=0, Withdrawn, ImmunityBio, Inc. | N=18 --> 0 | Not yet recruiting --> Withdrawn
Clinical • Enrollment change • Trial withdrawal
|
CD19 (CD19 Molecule)
|
CD19 expression
|
CD19.t-haNK